Article
Biochemistry & Molecular Biology
Alok Mishra, Anshuman Srivastava, Ankit Pateriya, Manendra Singh Tomar, Anand Kumar Mishra, Ashutosh Shrivastava
Summary: Breast cancer is the most common cancer among females, and endocrine therapy for ER-positive breast cancer can result in acquired resistance. The metabolic state of cancer cells plays a crucial role in their susceptibility to chemotherapeutic drugs, and understanding metabolic pathway alterations in TAMR cancer may offer potential therapeutic strategies.
CHEMICO-BIOLOGICAL INTERACTIONS
(2021)
Article
Oncology
Adam Hermawan, Herwandhani Putri, Naufa Hanif, Nurul Fatimah, Heri Himawan Prasetio
Summary: This study used a bioinformatics approach and in vitro experiments to assess the target genes of Honokiol (HON) against breast cancer resistance to tamoxifen (TAM). The results suggest that HON may overcome TAM resistance in breast cancer by targeting FGFR2, RET, ERBB4, MMP16, FN1, and SOX2. However, further studies are needed to validate these findings.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Xi Sun, Shuning Ding, Shuangshuang Lu, Zheng Wang, Xiaosong Chen, Kunwei Shen
Summary: Our study identified genes associated with tamoxifen resistance, especially those involved in the cell cycle pathway. These genes were validated to be up-regulated in tamoxifen-resistant patients and associated with poor prognosis in ER-positive patients. Targeting these genes may improve efficacy of endocrine therapy in breast cancer.
ONCOTARGETS AND THERAPY
(2021)
Article
Biochemistry & Molecular Biology
Mithila Sawant, Audrey Wilson, Dhivya Sridaran, Kiran Mahajan, Christopher J. O'Conor, Ian S. Hagemann, Jingqin Luo, Cody Weimholt, Tiandao Li, Juan Carlos Roa, Akhilesh Pandey, Xinyan Wu, Nupam P. Mahajan
Summary: Hormone receptor-positive, HER2-negative advanced breast cancers, which are sensitive to CDK4/6 inhibitors, often develop resistance. However, a study found that the non-receptor tyrosine kinase ACK1 is activated in breast cancer subtypes independent of hormone receptor status. Inhibition of ACK1 resulted in the suppression of cell cycle genes, leading to G2/M arrest and regression of palbociclib-resistant breast tumor growth. ACK1 inhibition also impaired the metastasis of breast cancer cells to the lung.
Article
Biology
Dylane Detilleux, Peggy Raynaud, Berengere Pradet-Balade, Dominique Helmlinger
Summary: Transcription factor TRRAP plays a crucial role in transcription activation as part of the SAGA and TIP60 complexes. Recent studies have revealed the involvement of the TTT subunit TELO2 in TRRAP assembly and its regulatory roles in colorectal cancer cells, including the regulation of MYC target genes and the unexpected induction of interferon genes. This study proposes a model in which TRRAP directly represses the transcription of IRF9, a master regulator of interferon-stimulated genes, revealing an unexpected repressor role for TRRAP.
Article
Biochemical Research Methods
Seunghyun Wang, Doheon Lee
Summary: In this study, two prognostic subgroups (BPS-LumA and WPS-LumA) of luminal-A breast cancer were identified using deep autoencoders and gene expressions. The prognostic difference between the two subgroups was validated using external datasets. The study also found that latent features were superior to gene expression profiles in discovering the prognostic subgroups.
PLOS COMPUTATIONAL BIOLOGY
(2023)
Article
Medicine, Research & Experimental
Sewon Hwang, Soojun Park, Jee Hyun Kim, Sang-Beom Bang, Hyeon-Ji Kim, Na-Lee Ka, Yoonae Ko, Seung-Su Kim, Ga Young Lim, Seunghee Lee, Young Kee Shin, So Yeon Park, Sanghee Kim, Mi-Ock Lee
Summary: This study aimed to identify lipid metabolic perturbations in tamoxifen-resistant breast cancer (BC) and investigate the role of HMGCS2 in BC growth. Comprehensive metabolomics and transcriptomics analysis were conducted. The upregulation of HMGCS2 was verified in tamoxifen-resistant BC cells and clinical samples. A HMGCS2 inhibitor was discovered and its effect on tumor growth was studied.
Article
Biochemistry & Molecular Biology
Nicole A. Traphagen, Sarah R. Hosford, Amanda Jiang, Jonathan D. Marotti, Brooke L. Brauer, Eugene Demidenko, Todd W. Miller
Summary: ER overexpression can lead to resistance to estrogen deprivation in ER+ breast cancer, but high levels of ER transcriptional activation can convert 17b-estradiol from a growth promoter to a growth suppressor, providing a targetable therapeutic vulnerability and a potential means of identifying patients likely to benefit from estrogen therapy.
Article
Microbiology
Gerard Badia-Bringue, Maria Canive, Patricia Vazquez, Joseba M. Garrido, Almudena Fernandez, Ramon A. Juste, Jose Antonio Jimenez, Oscar Gonzalez-Recio, Marta Alonso-Hearn
Summary: This study suggests that cows with higher levels of interferon-gamma (IFN-γ) may have better control of Mycobacterium avium subsp. paratuberculosis (MAP) infection. By measuring IFN-γ production in blood samples of 152 Holstein cattle, a specific genetic profile associated with high IFN-γ response was identified. These findings provide important insights into the host resistance mechanisms against MAP infection.
Review
Immunology
Dan Zhang, Aaron T. Irving
Summary: The interferon pathway is the first line of defense against viral infections in mammals, and it induces the expression of interferon-stimulated genes (ISGs). The antiviral function of ISGs has been extensively studied in mice and humans. Bats, as an important viral reservoir, can coexist with pathogenic viruses without showing signs of disease, but limited data are available on the role of ISGs in bats. This review summarizes the current understanding of conserved and bat-specific ISGs and their known antiviral functions.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Zhi Xu, Xiumei Wang, Wenbo Sun, Fan Xu, Hengyuan Kou, Weizi Hu, Yanyan Zhang, Qin Jiang, Jinhai Tang, Yong Xu
Summary: This study reveals the contribution of RelB-upregulated GPX4 in inhibiting ferroptosis to tamoxifen resistance in breast cancer.
Article
Oncology
Dawoon Jeong, Juyeon Ham, Hyeon Woo Kim, Heejoo Kim, Hwee Won Ji, Sung Hwan Yun, Jae Eun Parks, Keun Seok Lee, Heein Jo, Jai Hong Hang, So-Youn Jung, Seeyoun Lee, Eun Sook Lee, Han-Sung Kang, Sun Jung Kim
Summary: This study identified that the hypermethylation and downregulation of ELOVL2 gene in TamR breast cancer patients could lead to drug resistance, while its restoration significantly increased Tam sensitivity. The findings also revealed the potential role of ELOVL2 in regulating key genes involved in drug resistance pathways.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Medicine, Research & Experimental
Coralie Poulard, Thuy Ha Pham, Youenn Drouet, Julien Jacquemetton, Ausra Surmielova, Loay Kassem, Benoite Mery, Christine Lasset, Jonathan Reboulet, Isabelle Treilleux, Elisabetta Marangoni, Olivier Tredan, Muriel Le Romancer
Summary: Endocrine therapies targeting estrogen signaling have improved management of estrogen receptor alpha (ERα)-positive breast cancers. However, resistance to treatment remains a challenge. This study identifies nuclear PRMT5 expression as a predictive marker of sensitivity to tamoxifen in breast cancer patients, and reveals the mechanism of tamoxifen stimulating ERα methylation by PRMT5. This biomarker could be used to enhance response to tamoxifen in ERα-positive breast tumors.
EMBO MOLECULAR MEDICINE
(2023)
Article
Oncology
Belinda J. Petri, Kellianne M. Piell, Gordon C. South Whitt, Ali E. Wilt, Claire C. Poulton, Norman L. Lehman, Brian F. Clem, Matthew A. Nystoriak, Marcin Wysoczynski, Carolyn M. Klinge
Summary: The RNA binding protein and m6A reader HNRNPA2B1 is overexpressed in breast tumors compared to normal tissue. Overexpression of A2B1 leads to tamoxifen and fulvestrant resistance, while knockdown of A2B1 restores endocrine sensitivity. Targeting A2B1 could be a potential therapeutic strategy to overcome acquired endocrine resistance in breast cancer.
Article
Pharmacology & Pharmacy
Cheng Huang, Liangping Su, Yitian Chen, Sangqing Wu, Ruipu Sun, Qiuping Xu, Xiaoyi Qiu, Ciqiu Yang, Xiangzhan Kong, Hongquan Qin, Xinbao Zhao, Xue Jiang, Kun Wang, Yinghua Zhu, Ping-Pui Wong
Summary: Dysregulated sphingolipid metabolism contributes to ER+ breast cancer progression and therapeutic response. This study established sphingolipid metabolic enzyme CERK as a regulator of TAMR in breast cancer, demonstrating its role in tamoxifen resistance and tumor growth. Mechanistically, high CERK expression inhibits tamoxifen-induced sphingolipid ceramide accumulation, leading to tamoxifen resistance in TAMR cells. This work provides valuable insight into the regulation of sphingolipid metabolism and identifies a potential therapeutic target for tamoxifen resistance in breast cancer.
PHARMACOLOGICAL RESEARCH
(2023)